Aducanumab for Alzheimer's disease: An update

Authors

  • Thaarvena Retinasamy Neuropharmacology Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Selangor, Malaysia.
  • Mohd. Farooq Shaikh Neuropharmacology Research Strength, Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway 47500, Selangor, Malaysia.

DOI:

https://doi.org/10.31117/neuroscirn.v4i2.81

Keywords:

Alzheimer's disease, Amyloid beta, Aducanumab, Aduhlem, Neurodegeneration

Abstract

The US FDA approved Aducanumab in June 2021 as the first Alzheimer's disease (AD) drug under its accelerated approval pathway. It has given some hope to patients suffering from AD around the world. Aducanumab is an antibody that targets one of the well-known key culprits of this disease, known as amyloid-beta (Aβ). The journey of Aducanumab was bumpy, and there are controversies around the rapid approval of this drug AD treatment. This article highlights the potential of Aducanumab in AD, its mode of action and controversies around it.

References

Alzheimer's disease facts and figures. (2018). Alzheimer's & Dementia, 14(3), 367-429. https://doi.org/10.1016/j.jalz.2018.02.001

An, Y., Varma, V. R., Varma, S., Casanova, R., Dammer, E., Pletnikova, O., Chia, C. W., Egan, J. M., Ferrucci, L., Troncoso, J., Levey, A. I., Lah, J., Seyfried, N. T., Legido-Quigley, C., O'Brien, R., & Thambisetty, M. (2018). Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimer's & Dementia, 14(3), 318-329. https://doi.org/10.1016/j.jalz.2017.09.011

Bachmann, M. F., Jennings, G. T., & Vogel, M. (2019). A vaccine against Alzheimer's disease: anything left but faith? Expert Opinion on Biological Therapy, 19(1), 73-78. https://doi.org/10.1080/14712598.2019.1554646

Crehan, H., & Lemere, C. A. (2016). Chapter 7 - Anti-Amyloid-β Immunotherapy for Alzheimer's Disease. In M. S. Wolfe (Ed.), Developing Therapeutics for Alzheimer's Disease (pp. 193-226). Academic Press. https://doi.org/10.1016/B978-0-12-802173-6.00007-1

Cummings, J., Aisen, P., Lemere, C., Atri, A., Sabbagh, M., & Salloway, S. (2021). Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer's Research & Therapy, 13(1), 98. https://doi.org/10.1186/s13195-021-00838-z

Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016). Drug development in Alzheimer's disease: the path to 2025. Alzheimer's research & therapy, 8(1), 39. https://doi.org/10.1186/s13195-016-0207-9

Cummings, J. L., Morstorf, T., & Zhong, K. (2014). Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's research & therapy, 6(4), 37. https://doi.org/10.1186/alzrt269

Dunstan, R., Bussiere, T., Fahrer, D., Quigley, C., Zhang, X., Themeles, M., Engber, T., Rhodes, K., Arastu, M., & Li, M. (2011). Quantitation of beta-amyloid in transgenic mice using whole slide digital imaging and image analysis software. Alzheimer's & Dementia, 7(4, Supplement), S700. https://doi.org/10.1016/j.jalz.2011.05.2024

Farrimond, L. E., Roberts, E., & McShane, R. (2012). Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open, 2(3), e000917. https://doi.org/10.1136/bmjopen-2012-000917

Ferrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., & Sevigny, J. (2016). First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia, 2(3), 169-176. https://doi.org/10.1016/j.trci.2016.06.002

Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020). Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science, 27(1), 18-18. https://doi.org/10.1186/s12929-019-0609-7

Kent, S. A., Spires-Jones, T. L., & Durrant, C. S. (2020). The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics. Acta Neuropathologica, 140(4), 417-447. https://doi.org/10.1007/s00401-020-02196-w

Knopman, D. S., Jones, D. T., & Greicius, M. D. (2021). Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimer's & Dementia, 17(4), 696-701. https://doi.org/https://doi.org/10.1002/alz.12213

Marasco, R. A. (2020). Current and evolving treatment strategies for the Alzheimer disease continuum. American Journal of Managed Care, 26(8 Suppl), S167-s176. https://doi.org/10.37765/ajmc.2020.88481

Mullard, A. (2021). Landmark Alzheimer's drug approval confounds research community. Nature, 594(7863), 309-310. https://doi.org/10.1038/d41586-021-01546-2

Rajan, K. B., Wilson, R. S., Weuve, J., Barnes, L. L., & Evans, D. A. (2015). Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology, 85(10), 898. https://doi.org/10.1212/WNL.0000000000001774

Schneider, L. (2020). A resurrection of aducanumab for Alzheimer's disease. The Lancet Neurology, 19(2), 111-112. https://doi.org/10.1016/S1474-4422(19)30480-6

Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., & Kivipelto, M. (2014). Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. Journal of Internal Medicine, 275(3), 251-283. https://doi.org/10.1111/joim.12191

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O'Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H., … Sandrock, A. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature, 537(7618), 50-56. https://doi.org/10.1038/nature19323

Siemers, E. (2015). Drug Development in AD: Point of View from the Industry. Journal of Prevention of Alzheimer's Disease, 2(4), 216-218. https://doi.org/10.14283/jpad.2015.80

Singh, S. K., Srivastav, S., Yadav, A. K., Srikrishna, S., & Perry, G. (2016). Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting Aβ by Using Several Synthetic and Herbal Compounds. Oxidative medicine and cellular longevity, 2016, 7361613-7361613. https://doi.org/10.1155/2016/7361613

Downloads

Published

2021-06-30

How to Cite

Retinasamy, T., & Shaikh, M. F. (2021). Aducanumab for Alzheimer’s disease: An update. Neuroscience Research Notes, 4(2), 17–20. https://doi.org/10.31117/neuroscirn.v4i2.81

Issue

Vol. 4 No. 2 (2021): Regular Issue

Section

News and Views

Categories

License

Copyright (c) 2021 Thaarvena Retinasamy, Mohd. Farooq Shaikh

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The observations and associated materials published or posted by NeurosciRN are licensed by the authors for use and distribution in accord with the Creative Commons Attribution license CC BY-NC 4.0 international, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.